Investigational drug · Phase 3
SP-102
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Lumbosacral Radicular Pain.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
3
Any phase or sponsor naming "SP-102"
First trial start
2027
Feb 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SP-102", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lumbosacral Radicular Pain
Approved drugs for the same conditions: Pain and anesthesia
Largest trials
Live from ClinicalTrials.gov: studies naming "SP-102" as an intervention, largest first.
- Corticosteroid Lumbar Epidural Analgesia for Radicular Pain 2Pivotal-lookingNot yet recruiting
Semnur Pharmaceuticals, Inc.Industry
NCT07579351 · 755 participants (planned) · Start Feb 2027 · Primary completion Nov 2028
Drug: SP-102; Placebo and 1 more · For: Lumbosacral Radicular Pain
- Corticosteroid Lumbar Epidural Analgesia for RadiculopathyPivotal-lookingCompleted
Scilex Pharmaceuticals, Inc.Industry
NCT03372161 · 401 participants · Start Dec 8, 2017 · Primary completion Aug 20, 2021
Drug: SP-102; Placebo · For: Lumbosacral Radicular Pain
Sites: Mobile, Alabama; Phoenix, Arizona; Tempe, Arizona · 37 sites in all
Semnur Pharmaceuticals, Inc.Industry
NCT03613662 · 19 participants · Start Jul 13, 2018 · Primary completion Mar 15, 2019
Drug: SP-102 · For: Lumbosacral Radicular Pain
Sites: Boise, Idaho
Newest research
PubMed records naming it or its code names, newest first.
- Interpreting the totality of clinical study data: is there a better way? Statistical methodology for quantitatively interpreting clinical study data across efficacy endpoints.
Meske DS, Dworkin RH, Gudin J, et al. · Contemp Clin Trials 2026
- Evaluating IMMPACT Criteria for the Clinical Meaningfulness of Between-Group Differences: Interpreting Randomized Trial Results within a Context of Existing Chronic Pain Analgesics.
Meske DS, Dworkin RH, Gudin J, et al. · J Pain Res 2026
- Long-acting dexamethasone viscous gel (SP-102) transforaminal injection for lumbosacral radicular pain.
Knezevic NN, George C, Ferrer Gonzalez DA · Pain Manag 2026
- An Evaluation of the Impact of Air Pollution on the Lung Functions of High School Students Living in a Ceramic Industrial Park Zone.
Mizutani RF, de Paula Santos U, Arbex RF, et al. · Int J Environ Res Public Health 2023
- Clinical outcomes and cost-effectiveness of superficial parotidectomy versus extracapsular dissection of the parotid gland: a single-centre retrospective study of 161 patients.
Vanroose R, Scheerlinck J, Coopman R, et al. · Int J Oral Maxillofac Surg 2023
- The pharmacokinetics and pharmacodynamics of dexamethasone following epidural SP-102 or intravenous dexamethasone sodium phosphate injection in subjects with lumbosacral radicular pain.
Yee S, Robson R, Stannard E, et al. · Int J Clin Pharmacol Ther 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.